Paroxetine-induced bruxism effectively treated with tandospirone [8]

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 19, Issue 1, 2007, Pages 90-91

  Kishi, Yasuhiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTORECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PAROXETINE; SEROTONIN 1A RECEPTOR; SULPIRIDE; TANDOSPIRONE;

AGED; BRUXISM; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; FOLLOW UP; HUMAN; JAPANESE; LETTER; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 33847133548     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2007.19.1.90     Document Type: Letter

References (6)

1. Winocur E, Gavish A, Voikovitch M, et al: Drugs and bruxism: a critical review. J Orofac Pain 2003; 17:99-111
2. Hamik A, Oksenberg D, Fischette C, et al: Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990; 28:99-109
3. th ed. Washington, DC, American Psychiatric Publishing, 1994, pp 339-344
4. Bostwick JM, Jaffee MS: Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry 1999; 60:857-860
5. Tanda G, Carboni E, Frau R, et al: Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) 1994; 115:285-288
6. Sakaue M, Somboonthum P, Nishihara B, et al: Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 2000; 129:1028-1034